Amit Sachdev, MD, MS’ Post

A recent study published in JAMA Neurology found that monthly injections of erenumab are effective in reducing medication overuse headaches (MOH) in people with chronic migraines who are not using opioids. The study included 584 participants who were given either 70 mg or 140 mg of erenumab or a placebo over 24 weeks. At the six-month mark, 69.1% of participants in the 140-mg group and 60.3% in the 70-mg group saw improvements in their headaches, compared to 52.6% of those on the placebo. The 140-mg group also reduced their use of headache medication by an average of 9.4 days per month. The study suggests that erenumab may offer an effective treatment for people struggling with chronic migraines and MOH. The treatment’s safety profile was consistent with earlier studies, with the most common side effect being constipation. This is the first controlled trial showing significant benefits for a migraine prevention treatment in this patient group. #neurology #headache #medicationoveruseheadache #migraine With the Specialist combines artificial intelligence with a board certified neurologist to enhance neurological care, bringing the neurology consult to you. #withthespecialist #aiinhealthcare #innovation https://lnkd.in/gsTZ32Yx https://lnkd.in/gExrwg2P

Healio Spotlighted Spherix's research on Leqembi for Alzheimer's treatment. Spherix's results revealed that patient requests are driving demand as well as some clinician optimism in Leqembi’s efficacy.   According to Alissa Algarin, Spherix's Neurology Insights Director, "Few surveyed neurologists considered Leqembi to be a significant medical advance over other historical Alzheimer’s treatments and satisfaction with Leqembi was low compared to Spherix neurology launch benchmarks.”    For more insights, check out the full article here: https://lnkd.in/ejyzAq76   #Neurology #AlzheimersDisease #Healio #Leqembi

At the 2024 American Academy of Neurology conference, significant findings were unveiled regarding the efficacy and safety of Ocrelizumab in the treatment of multiple sclerosis (MS). Insights from the Phase IIIb ENSEMBLE Trial and the Matched Real-world NTD MS Registry Cohort revealed sustained low disease activity over four years of Ocrelizumab therapy in treatment-naive patients with high-activity, early-stage relapsing-remitting MS. Moreover, the ENSEMBLE Study showcased promising outcomes of 10 years of Ocrelizumab treatment, demonstrating its enduring efficacy and safety. Additionally, results from the OCARINA II Phase III Study highlighted the effectiveness of subcutaneous administration of Ocrelizumab in Multiple Sclerosis patients. Read more about RRMS treatment options @ https://lnkd.in/gu5sF5Ve #AAN2024 #Ocrelizumab #MultipleSclerosis #NeurologyConference #ENSEMBLEtrial #OCARINAII #MSresearch

AstraZeneca Case Series Shows Long-Term Efficacy and Convenience of Ravulizumab in Generalized Myasthenia Gravis #neurology NeurologyLive https://lnkd.in/gWdHebPN

Fierce Pharma recently revisited Spherix's research regarding neurologists' perceptions of Leqembi for Alzheimer's Disease (AD), echoing a previous article from February discussing Leqembi's launch.   One of the key Spherix findings Fierce Pharma called out was how few surveyed neurologists have been recommending Leqembi to patients.   Read the full article here: https://lnkd.in/etnCdctf   #AlzheimersDisease #Neurology #FiercePharma #Leqembi

https://lnkd.in/e8WXyJp5 #DMD is getting crowded and yet, safe and effective treatments remain a long ways away. "patients treated with #Duvyzat showed statistically significant less decline in the time it took to climb #fourstairs compared to placebo. The mean change from baseline to Month 18 in time to climb four stairs was 1.25 seconds for patients receiving Duvyzat compared to 3.03 seconds for patients receiving placebo. " It is not clear to me that combining steroids and NSAIDs reflects the best managent plan for your boys with #Duchenne. This conversation will come down to real world safety data. #newdrugapproval #medicine #neurology

A Case of Myasthenia Gravis https://lnkd.in/dZvydxbC  This article delves into the pathophysiology, symptoms, and diagnostic criteria of Myasthenia Gravis. It also emphasises current treatment methods and advancements to improve patient outcomes.1. #MyastheniaGravis #Neurology #MedicalResearch #TreatmentAdvancements #PatientOutcome #RareDisease #HealthcareAdvances #NeuromuscularDisorder #DiseaseAwareness #MedicalInnovation

Combining therapies for better outcomes: Our research indicates that integrating neuromodulation with traditional pharmacological treatments could offer synergistic benefits for Parkinson's patients. How do you envision the future of multi-modal treatment approaches in neurology? What potential combinations excite you the most? Explore the possibilities in our comprehensive review: https://lnkd.in/dmKm45VQ #IntegrativeMedicine #NeurologicalTreatment #TherapeuticInnovation

Discover the role of phosphorylated tau protein (p-Tau 181) in neurodegenerative diseases and advance your neurology research from discovery to the clinic with p-tau 181 ➡️ #Alzheimers #ptau181 #neurology #clinicalresearch

Discover the role of phosphorylated tau protein (p-Tau 181) in neurodegenerative diseases and advance your neurology research from discovery to the clinic with p-tau 181 ➡️ #Alzheimers #ptau181 #neurology #clinicalresearch